Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: A Phase IIa Study

Leukemia

Volumn 31, Issue 4, 2017, Pages 997-1000

  Ludwig, H ^a   Weisel, K ^b   Petrucci, M T ^c   Leleu, X ^d   Cafro, A M ^e   Garderet, L ^f   Leitgeb, C ^a   Foa, R ^c   Greil, R ^g   Yakoub Agha, I ^h   Zboralski, D ⁱ   Vauleon S ⁱ   Dummler T ⁱ   Beyer, D ⁱ   Kruschinski, A ⁱ   Riecke, K ⁱ   Baumann, M ⁱ   Engelhardt, M ^j  

^a WILHELMINEN HOSPITAL   (Austria)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f HÔPITAL SAINT ANTOINE   (France)

^g PARACELSUS MEDICAL UNIVERSITY   (Austria)

^h UNIVERSITÉ DE LILLE   (France)

ⁱ NOXXON PHARMA AG   (Germany)

^j UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD38 ANTIGEN; DEXAMETHASONE; OLAPTESED PEGOL; STROMAL CELL DERIVED FACTOR 1; SYNDECAN 1; ANTINEOPLASTIC AGENT; CXCL12 PROTEIN, HUMAN; OLIGORIBONUCLEOTIDE; PROTEASOME;

ANEMIA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG DOSE ESCALATION; ELIMINATION HALF-LIFE; HUMAN; LETTER; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FEMALE; MALE; METABOLISM; MIDDLE AGED;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; CHEMOKINE CXCL12; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OLIGORIBONUCLEOTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 85011599021     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.5     Document Type: Letter

References (15)

1. Bouyssou JM, Ghobrial IM, Roccaro AM. Targeting SDF-1 in multiple myeloma tumor microenvironment. Cancer Lett 2015; 380: 315-318
2. Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C et al. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep 2014; 9: 118-128
3. Martin SK, Dewar AL, Farrugia AN, Horvath N, Gronthos S, To LB et al. Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma. Clin Cancer Res 2006; 12: 6973-6977
4. Vater A, Sahlmann J, Kroger N, Zollner S, Lioznov M, Maasch C et al. Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clin Pharmacol Ther 2013; 94: 150-157
5. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-toevent results of the APEX trial. Blood 2007; 110: 3557-3560
6. Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van Velde H et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012; 97: 1925-1928
7. Harrison SJ, Quach H, Link E, Feng H, Dean J, Copeman M et al. The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit. Am J Hematol 2015; 90: E86-E91
8. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014; 15: 1195-1206
9. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17: 27-38
10. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 754-766
11. Dimopoulos MA, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E et al. Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica 2013; 98: 1264-1272
12. Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014; 123: 985-991
13. Ghobrial IM, Perez R, Baz R, Richardson PG, Anderson KC, Sabbatini P et al. Phase Ib study of the novel anti-CXCR4 antibody ulocuplumab (BMS-936564) in combination with lenalidomide plus low-dose dexamethasone, or with bortezomib plus dexamethasone in subjects with relapsed or refractory multiple myeloma. Blood 2014; 124: 3483
14. Ghobrial IM, Shain KH, Laubach J, Henrick P, Vredenburg J, Crilley P et al. Final results of the phase I/II study of chemosensitization using the CXCR4 inhibitor plerixafor in combination with bortezomib in patients with relapsed or relapsed/ refractory multiple myeloma. Blood 2015; 126: 4256
15. Azab AK, Sahin I, Moschetta M, Mishima Y, Burwick N, Zimmermann J et al. CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. Blood 2014; 124: 1905-1914